John Garcia, MD
Internal Medicine · Chesterfield, MONPI 1649294554
Payments from drug & device makers
Across 133 payments — averaging $25.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- AstraZeneca$479
- Gilead$240
- Bayer$190
- Biohaven Pharmaceuticals, Inc.$183
- Inari Medical, Inc.$181
- plus $363 from 11 others
What the payments were for
- Food & beverage$3,450100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 85 | $1,815 |
| AstraZeneca | 10 | $479 |
| Gilead | 4 | $240 |
| Bayer | 6 | $190 |
| Biohaven Pharmaceuticals, Inc. | 6 | $183 |
| Inari Medical, Inc. | 1 | $181 |
| Novartis | 5 | $76 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $60 |
| Scilex Pharmaceuticals Inc. | 1 | $49 |
| Kaleo, Inc. | 1 | $38 |
| Pfizer | 2 | $31 |
| Eisai Inc. | 2 | $29 |
| Novo Nordisk | 2 | $27 |
| Amarin Pharma, Inc. | 1 | $15 |
| Abbott | 1 | $14 |
| Grifols USA, LLC | 1 | $13 |
| Cumberland Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$242
- FLOWTRIEVER CATHETER, S$181
- CT THROMBECTOMY SYSTEM KIT$181
- NURTEC ODT$125
- Kerendia$113
- VRAYLAR$112
- Epclusa$106
How this compares
$3,450 in reported general payments places this provider in the 85th percentile of 2,097 internal medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Albuterol Sulfate HfaAlbuterol Sulfate | 21 | $804 |
| Cyclobenzaprine Hcl | 12 | $609 |
| Cefdinir | 23 | $427 |
| Levothyroxine Sodium | 13 | $274 |
| Trazodone Hcl | 13 | $255 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 16 | $207 |
| Simvastatin | 33 | $171 |
| Metoprolol Succinate | 20 | $138 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 16 | $127 |
| Pantoprazole Sodium | 14 | $126 |
| Gabapentin | 14 | $119 |
| Lisinopril | 23 | $110 |
| Losartan Potassium | 13 | $106 |
| Omeprazole | 15 | $98 |
| Diazepam | 17 | $93 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Chesterfield
- Jianbo WangChesterfield$643K
- Timothy SmithSaint Peters$21.4M
- Craig DietzKansas City$4M
- Michael ReschakSaint Louis$3.1M
- Dima DandachiColumbia$1.2M
- Santosh SharmaKansas City$782K
- David PrelutskySaint Louis$575K
- Danish JabbarSaint Louis$510K
- Dubert GuerreroIndependence$369K
- Hany SalamaSaint Louis$279K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.